These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. Sanfilippo CM; Allaire CM; DeCory HH Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599 [TBL] [Abstract][Full Text] [Related]
7. The role of besifloxacin in the treatment of bacterial conjunctivitis. Mahvan TD; Hornecker JR; Buckley WA; Clark S Ann Pharmacother; 2014 May; 48(5):616-25. PubMed ID: 24566460 [TBL] [Abstract][Full Text] [Related]
8. Besifloxacin in the management of bacterial infections of the ocular surface. Deschênes J; Blondeau J Can J Ophthalmol; 2015 Jun; 50(3):184-91. PubMed ID: 26040217 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Comstock TL; Paterno MR; Usner DW; Pichichero ME Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747 [TBL] [Abstract][Full Text] [Related]
10. Besifloxacin ophthalmic suspension 0.6%. Carter NJ; Scott LJ Drugs; 2010; 70(1):83-97. PubMed ID: 20030427 [TBL] [Abstract][Full Text] [Related]
11. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842 [TBL] [Abstract][Full Text] [Related]
12. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin. Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963 [TBL] [Abstract][Full Text] [Related]
13. Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods. Tótoli EG; Salgado HRN Crit Rev Anal Chem; 2018 Mar; 48(2):132-142. PubMed ID: 29345957 [TBL] [Abstract][Full Text] [Related]
14. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. DeCory HH; Sanfilippo CM; Proskin HM; Blondeau JM PLoS One; 2020; 15(8):e0237603. PubMed ID: 32841261 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770 [TBL] [Abstract][Full Text] [Related]
16. The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis. Malhotra R; Ackerman S; Gearinger LS; Morris TW; Allaire C Drugs R D; 2013 Dec; 13(4):243-52. PubMed ID: 24142473 [TBL] [Abstract][Full Text] [Related]